在心誠鎂（HCmed），我們尋找的不決是員工，而是未來的核心領導者。作為全球指標性大藥廠值得信賴的戰略夥伴，我們提供專為有抱負的年輕專業人才打造的高規格儲備幹部（MA）計畫。在這裡，你將深入鑽研藥械合一產品的核心商業模式，並挑戰真實的國際專案，快速培養策略視野與領導能力。

我們非常榮幸地宣布，心誠鎂的智慧型呼吸偵測式霧化裝置 AdheResp® 已正式獲得台灣食藥署（TFDA）認證！

心誠鎂新廠正式啟用，擴大產能全力支援國際吸入市場供應鏈 ！ 專注於吸入式藥械合一產品開發的 心誠鎂行動醫電，全新廠房已於今日正式落成啟用！

心誠鎂攜手美國藥廠夥伴 獲首階段開發里程碑金

The first and only FDA 510(k)-cleared breath-actuated mesh nebulizer with built-in connectivity as part of its cleared design!

HCmed Innovations Co., Ltd Appoints Chris Vernall as Executive Vice President of Business Development

✉️超越期望——來自 HCmed 執行長的一封信

HCmed is thrilled to announce the launch of our new logo!

心誠鎂按時完成美國獨角獸罕病公司早期開發研究專案，依照會計準則，按合約進度於2024年前兩季認列開發收入。

On March 3rd, HCmed hosted a lunch symposium at Chung Shan Medical University Hospital. During the event, we introduced our Pulmogine vibrating mesh nebulizer to pediatricians and nursing staff at the medical center.

HCmed is proud to announce that our Pulmogine Vibrating Mesh Nebulizer has been approved by the U.S. Food and Drug Administration (FDA) for use with Pulmozyme, a widely prescribed medication for cystic fibrosis patients.

As HCmed Innovations celebrates its 10th year in operation, our CEO, Jason Cheng, has unveiled a bold set of New Year resolutions aimed at propelling the organization to new heights.

We're excited to unveil our new HCmed UK site, located in Chichester, West Sussex UK.

HCmed announced the appointment of Gunilla Petersson, Ph.D. as the new Chief Scientific Officer (CSO).

Dr. Shao Chi Huang this month shares his experience working in the clinical field.